- Samsung Bio to step into peptides in $1.8B buy for PolyPeptideSamsung Biologics is set to branch out to peptide ingredient manufacturing with plans to buy Swiss CDMO PolyPeptide for $1.8 billion in cash. The purchase, announced Monday, would be the Korean ...Endpoints · 8d ago↗ source
- Pain drugmaker Latigo outlines plans to go publicThe Westlake-founded company specializes in non-opioid drugs that target sodium ion channels, and is now adding to what’s already been a busy month for the biotech IPO queue.BioPharma Dive · 8d ago↗ source
- Anthropic's life sciences plans: Mystery programs, Nobel hires, M&A and big ambitionA year ago, Anthropic’s life sciences plans were basically just a blog post by its CEO. In late 2024, Dario Amodei wrote a 13,000-word memo naming biology and neuroscience among his ...